Short answer
Claritev Corp (CTEV) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $268M (up 9.1% year over year) with net income of −$62M.
Q3 2026 key financials · XBRL
- Revenue
- $268M
- +9.1% YoY · +4.2% QoQ
- Net income
- −$62M
- +11.4% YoY · −4.3% QoQ
- Operating margin
- 7.7%
- EPS (diluted)
- −$3.64
- +13.9% YoY · −4.6% QoQ
Source: XBRL data from the Claritev Corp (CTEV) Q3 2026 10-Q on SEC EDGAR. USD.
Claritev Corp Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $268.3M, up 9.1% YoY from $246.0M
- Operating margin 7.7% vs 4.1% YoY, net loss $61.8M vs $69.8M
- Best segment: Claims intelligence revenue $192.5M, up 17.1%; worst: Payment and revenue integrity $25.9M, down 9.8%
- Cash balance $23.0M, operating cash flow $65.0M, investing outflow $128.8M
- Outlook: liquidity sufficient for next twelve months, with technology investments and antitrust legal expenses as headwinds
Risk Factors
- DOJ civil investigative demand received May 19, 2026, with inquiry ongoing after separate antitrust proceeding closure
- Regulatory risk: evolving healthcare laws may increase litigation exposure for cost management providers
- Legal risk: provider and member litigation increasingly multi-party, multi-claim, or class-wide
- Financial risk: uninsured or insufficiently insured litigation losses could materially affect results
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Claritev Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.